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Triple-negative breast cancer (TNBC) is a more aggressive breast cancer with a poorer prognosis 
than other types of breast cancer. TNBC mortality is 42% higher in African American women 
compared to other American women, which is one of the most significant examples of racial 
disparity in oncology. TNBC does not express the common receptors estrogen and progesterone 
or the human epidermal growth factor receptor 2 (HER2), making targeted hormone therapies 
ineffective. Thus, there is an urgent medical need for the development of novel potential drug 
candidates for TNBC. In clinics, platinum-based regimes provide overall survival advantages for 
TNBC patients compared to non-platinum regimens. It was recently shown that Arsenic Trioxide 
alone or in combination with other therapeutics such as Cisplatin inhibits the growth of triple-
negative breast cancer cells in vitro and in vivo. The synergy between Cisplatin and Arsenic 
Trioxide was established in a variety of triple-negative breast cancer cell lines. This inspired us 
to synthesize a new class of anticancer agents that contain pharmacophores of both drugs, which 
we refer to as arsenoplatins. According to the NCI-60 screen (NCI, National Cancer Institute), 
the first member of this class, Arsenoplatin-1 (AP-1), has shown better anticancer activity than 
Arsenic Trioxide in all 9 tumor types tested and better than Cisplatin in 4 indications and 
comparable in two. Importantly, according to this screen, AP-1 is the most potent against triple-
negative breast cancer cell lines. Several new arsenoplatin compounds are synthesized and 
characterized. The results of in vitro studies of new arsenoplatin compounds against triple-
negative breast cancer cell lines will be presented. These results are the first step in determining 
the lead compound for in vivo studies, which may lead to develop a potential therapeutic drug 
candidate against TNBC.  
 
 
